thought rais pt
remain larg neutral agricultur believ
differenti fundament view present within equal-weight ag
construct best class multi-year growth stori function
innov product penetr rather cyclic dynam believ
well understood bayer remain ag overweight lead coverag joseph
lockey believ differenti view
glyphos litig compani face note investor sentiment
ag appear upsw investor alreadi bake upcycl
someth readi call one way present
oper result solid outlook remain intact
despit well understood challeng face north american market
earn estim larg unchang simpli move penni
ep base compani updat guidanc
contrast peer compani estim outlook declin
significantli into/aft quarter yet share price gener increas
confer call also provid detail updat
signific patent protect enjoy industri lead diamid
franchis well road map post-pat life franchis
view patent expiri would prove manag
equiti market think risk investor concern
expiri would hold compani multipl back believ
today present like help amelior concern
simpli put indic third parti unabl enter market
chlorantraniliprol rynaxypyr least china
 india brazil us europ due confluenc
composit matter patent activ ingredi certain intermedi ii
process patent ai key intermedi iii formul patent iv use
patent applic patent greater diamid patent
famili countri across patent process/tim vari region
also includ data protect ai/product registr protect
certain market refer detail slides/transcript explicit
detail compani indic dynam effect
chemic unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
cyazypyr though time line go month later
said third parti sell either product prior date long
suppli licens expect win/win
continu insid
end compani indic commerci agreement place
activ discuss compani suppli product note
like outcom seen monsanto creat win/win situat
glyphos post-pat also like someth mani investor
fulli appreci third parti like work given favor asset
lite econom licens avoid invest complex manufactur
process suppli chain etc purchas high qualiti product reason price
benefit increas economi scale sg spend
increment licens volum net licens volum ebitda dilut
offer good margin competitor
rais price target prior price target assum price-to-earnings
ev/ebitda multipl low end histor ag seed crop chemic peer
rang subsequ broader agricultur oper environ improv
challeng north american grow condit like produc less suppli
previous anticip prospect reliev demand anxieti
associ african swine flu perk soft commod price investor
sentiment process net also believ ag earn multipl
discount rate like gravit higher lower respect cyclic
risk/reward least favor said maintain
wait see approach ag cycl see mani cross current
convict sustain upcycl end note decemb corn
price key benchmark price view alreadi come
challeng us plant high ep estim larg unchang
post note ep estim peer gener move lower
share price increas nonetheless impli higher rel valuat
multipl support higher multipl
price target triangul assess ebitda multipl
could get next month pipelin valuat work dcf
analysi suggest exist busi worth per share
pipelin risk-adjust valu per share price target triangul
ebitda price-to-earnings look
transitori cost/weath reason histor pure-play ag compani
trade premium non pure-play compani make sens us exampl
monsanto histor trade ev/ebitda rang
price target triangul dcf analysi suggest
exist busi worth pipelin
risk-adjust valu ebitda multipl
toward upper end histor seed/crop chemic pure play
valuat re-rat best class growth transcend ag peer valuat
multipl histori revenu compound-annual-growth-rate pipelin hit rate appear greater
expect sale target appear conserv becom appar
ebitda margin expand expect
like convers better expect capit return sharehold ahead
expect
statu quo persist revenu compound-annual-growth-rate price sticki raw
materi availability/cost pressure/tariff issu fx headwind ultim
abat sap convers goe smoothli convers improv expect
patent licens plan execut pipelin product launch time
ramp toward peak sale ebitda margin expand expect
patent concern linger diamid address market smaller expect
regulatori environ slow product registr product pipelin
move slowli diamid sale volum slow rais concern
enough room licens volum chines gener competit pipelin
product struggl regulatori registr launch late slower
within equal-weight ag construct
best class multi-year growth stori
function innov product
penetr rather cyclic dynam
believ well understood
lot equiti market like visibl
market growth sale compound-annual-growth-rate
versu industri ii
portfolio less reliant peer us/latam
 corn soybean drive growth iii
crop chemic seed busi
held back recent year lack
price/mix expens digit ag
remain larg neutral agricultur
believ differenti
fundament view present though
note investor sentiment ag appear
upsw investor alreadi
bake upcycl someth
readi call one way
diamid franchis
pipelin product advanc
risk achiev price
diamid address market smaller
unabl off-set margin pressur
fx raw materi headwind
convers improv much
expect
methodolog bayer overweight price target
price target weight combin dcf-base bull base
scenario bear case base past trough multipl ep wacc
termin growth revers roce cost capit long term
appli weight bull case weight base case
weight bear case weight reflect current view rel
likelihood scenario play
 execut consum health turnaround
 perform xarelto eylea
 progress divest consum brand anim divis
risk achiev price target
 upsid risk posit appeal johnson case ag cycl recoveri posit pipelin news
 downsid risk neg litig progress ag disrupt pipelin failur failur
